doi: 10.1016/j.injury.2004.12.037 182 MorrisGBerkMGaleckiPMaesM
These enzymes can be used to metabolize ECM structural components (Wang et al., 2023) and reduce biofilm differentials by converting sessile cells into planktonic cells that are more susceptible to antimicrobial therapy
Understanding the structural characteristics, release mechanisms, and clinical application differences of these two types of linkers is of great significance for optimizing ADC design, improving efficacy, and ensuring safety
Retatrutide (triple agonist, investigational) Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors
Patient Support Hub Programs: An End-to-End Guide Learn about patient support hub programs in specialty pharma
I have to say after a little bit of an adjustment period you can really feel this stuff working